CA2961380A1 - Methods and compositions for treating psychotic disorders - Google Patents

Info

Publication number

CA2961380A1

CA2961380A1 CA2961380A CA2961380A CA2961380A1 CA 2961380 A1 CA2961380 A1 CA 2961380A1 CA 2961380 A CA2961380 A CA 2961380A CA 2961380 A CA2961380 A CA 2961380A CA 2961380 A1 CA2961380 A1 CA 2961380A1

Authority

CA

Canada

Prior art keywords

glutathione

cysteine

ebselen

nvhl

rats

Prior art date

2014-09-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 68
• 208000028017 Psychotic disease Diseases 0.000 title claims abstract description 25
• 239000000203 mixture Substances 0.000 title description 35
• 150000001875 compounds Chemical class 0.000 claims abstract description 106
• 102000006587 Glutathione peroxidase Human genes 0.000 claims abstract description 82
• 108700016172 Glutathione peroxidases Proteins 0.000 claims abstract description 82
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 44
• 239000000164 antipsychotic agent Substances 0.000 claims abstract description 27
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
• 230000001404 mediated effect Effects 0.000 claims abstract description 21
• 239000000890 drug combination Substances 0.000 claims abstract description 3
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 231
• 229960003180 glutathione Drugs 0.000 claims description 116
• 201000000980 schizophrenia Diseases 0.000 claims description 101
• DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 claims description 96
• 229960004308 acetylcysteine Drugs 0.000 claims description 89
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 88
• 229950010033 ebselen Drugs 0.000 claims description 88
• 230000036542 oxidative stress Effects 0.000 claims description 68
• 230000000694 effects Effects 0.000 claims description 52
• 108010024636 Glutathione Proteins 0.000 claims description 41
• 239000000651 prodrug Substances 0.000 claims description 31
• 229940002612 prodrug Drugs 0.000 claims description 31
• -1 phenylacetyl Chemical group 0.000 claims description 24
• 235000018417 cysteine Nutrition 0.000 claims description 23
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 23
• 239000011669 selenium Substances 0.000 claims description 22
• 239000003814 drug Substances 0.000 claims description 17
• 229910052711 selenium Inorganic materials 0.000 claims description 17
• 229960001076 chlorpromazine Drugs 0.000 claims description 16
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 16
• PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 claims description 16
• MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 16
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
• 150000003839 salts Chemical class 0.000 claims description 13
• 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 11
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
• 208000024891 symptom Diseases 0.000 claims description 9
• CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 8
• SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 8
• PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 8
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 8
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 8
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
• 229960002690 fluphenazine Drugs 0.000 claims description 8
• 229940003380 geodon Drugs 0.000 claims description 8
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 8
• 229940036674 latuda Drugs 0.000 claims description 8
• 229960001432 lurasidone Drugs 0.000 claims description 8
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 8
• 229960004431 quetiapine Drugs 0.000 claims description 8
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 8
• ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 claims description 8
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 8
• 229940035004 seroquel Drugs 0.000 claims description 8
• 229960000607 ziprasidone Drugs 0.000 claims description 8
• PMXMIIMHBWHSKN-LJQANCHMSA-N (R)-paliperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCC[C@@H](O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-LJQANCHMSA-N 0.000 claims description 7
• 208000019901 Anxiety disease Diseases 0.000 claims description 7
• 229920000858 Cyclodextrin Polymers 0.000 claims description 7
• 206010026749 Mania Diseases 0.000 claims description 7
• RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 7
• 239000008103 glucose Substances 0.000 claims description 7
• 229960000762 perphenazine Drugs 0.000 claims description 7
• IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 claims description 6
• 229910052757 nitrogen Inorganic materials 0.000 claims description 5
• UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 claims description 4
• MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 claims description 4
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 4
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 4
• ZFAHNWWNDFHPOH-YFKPBYRVSA-N S-allylcysteine Chemical compound OC(=O)[C@@H](N)CSCC=C ZFAHNWWNDFHPOH-YFKPBYRVSA-N 0.000 claims description 4
• ULXKXLZEOGLCRJ-BYPYZUCNSA-N S-ethyl-L-cysteine zwitterion Chemical compound CCSC[C@H](N)C(O)=O ULXKXLZEOGLCRJ-BYPYZUCNSA-N 0.000 claims description 4
• 150000001323 aldoses Chemical class 0.000 claims description 4
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 4
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
• SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 claims description 4
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 4
• 229930182830 galactose Natural products 0.000 claims description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
• 125000004043 oxo group Chemical group O=* 0.000 claims description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
• IDIDJDIHTAOVLG-UHFFFAOYSA-N S-methyl-L-cysteine Natural products CSCC(N)C(O)=O IDIDJDIHTAOVLG-UHFFFAOYSA-N 0.000 claims description 3
• WAAGBMYUYFBZIW-UHFFFAOYSA-N S-propylcysteine Chemical compound CCCSCC(N)C(O)=O WAAGBMYUYFBZIW-UHFFFAOYSA-N 0.000 claims description 3
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 3
• 230000000561 anti-psychotic effect Effects 0.000 claims description 3
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
• ZFAHNWWNDFHPOH-UHFFFAOYSA-N S-Allyl-L-cystein Natural products OC(=O)C(N)CSCC=C ZFAHNWWNDFHPOH-UHFFFAOYSA-N 0.000 claims description 2
• 229960004372 aripiprazole Drugs 0.000 claims description 2
• 238000006467 substitution reaction Methods 0.000 claims description 2
• DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical group OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 claims description 2
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 4
• MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims 1
• CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
• 229940124597 therapeutic agent Drugs 0.000 claims 1
• 238000011282 treatment Methods 0.000 abstract description 80
• 208000035475 disorder Diseases 0.000 abstract description 24
• 230000003278 mimic effect Effects 0.000 abstract description 17
• 201000010099 disease Diseases 0.000 abstract description 16
• 230000002265 prevention Effects 0.000 abstract description 5
• 230000005764 inhibitory process Effects 0.000 abstract description 3
• 230000007774 longterm Effects 0.000 abstract description 2
• 241000700159 Rattus Species 0.000 description 112
• 210000002442 prefrontal cortex Anatomy 0.000 description 51
• 102000001675 Parvalbumin Human genes 0.000 description 39
• 108060005874 Parvalbumin Proteins 0.000 description 39
• 230000006735 deficit Effects 0.000 description 38
• 230000003902 lesion Effects 0.000 description 36
• 230000000366 juvenile effect Effects 0.000 description 28
• 210000002569 neuron Anatomy 0.000 description 21
• DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 20
• 210000004027 cell Anatomy 0.000 description 20
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 20
• 230000002829 reductive effect Effects 0.000 description 20
• HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 19
• 230000001054 cortical effect Effects 0.000 description 19
• 210000004556 brain Anatomy 0.000 description 18
• 230000001965 increasing effect Effects 0.000 description 18
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 17
• 230000007246 mechanism Effects 0.000 description 17
• 239000003963 antioxidant agent Substances 0.000 description 16
• 235000006708 antioxidants Nutrition 0.000 description 16
• 210000001153 interneuron Anatomy 0.000 description 16
• 210000001176 projection neuron Anatomy 0.000 description 16
• 108010043166 wisteria lectin Proteins 0.000 description 16
• 230000003078 antioxidant effect Effects 0.000 description 15
• 230000006870 function Effects 0.000 description 15
• 238000012360 testing method Methods 0.000 description 15
• 241001465754 Metazoa Species 0.000 description 14
• 238000002372 labelling Methods 0.000 description 14
• 235000021251 pulses Nutrition 0.000 description 14
• 210000004515 ventral tegmental area Anatomy 0.000 description 14
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
• 229940079593 drug Drugs 0.000 description 13
• 238000001727 in vivo Methods 0.000 description 13
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 12
• 230000015572 biosynthetic process Effects 0.000 description 12
• 238000002474 experimental method Methods 0.000 description 12
• 229930195712 glutamate Natural products 0.000 description 12
• 239000007788 liquid Substances 0.000 description 12
• 230000004044 response Effects 0.000 description 12
• 230000000638 stimulation Effects 0.000 description 12
• 108010053070 Glutathione Disulfide Proteins 0.000 description 11
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 11
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 11
• 238000009472 formulation Methods 0.000 description 11
• YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 11
• FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 10
• 241000282414 Homo sapiens Species 0.000 description 10
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 10
• 230000002159 abnormal effect Effects 0.000 description 10
• 238000010171 animal model Methods 0.000 description 10
• 229930188866 apocynin Natural products 0.000 description 10
• 239000002775 capsule Substances 0.000 description 10
• 229960003638 dopamine Drugs 0.000 description 10
• 239000002552 dosage form Substances 0.000 description 10
• 239000003937 drug carrier Substances 0.000 description 10
• 230000010355 oscillation Effects 0.000 description 10
• 108090000623 proteins and genes Proteins 0.000 description 10
• 150000003254 radicals Chemical class 0.000 description 10
• 239000003642 reactive oxygen metabolite Substances 0.000 description 10
• 230000001225 therapeutic effect Effects 0.000 description 10
• 102000003992 Peroxidases Human genes 0.000 description 9
• 239000004480 active ingredient Substances 0.000 description 9
• 230000004075 alteration Effects 0.000 description 9
• 239000000090 biomarker Substances 0.000 description 9
• 230000002354 daily effect Effects 0.000 description 9
• 238000011161 development Methods 0.000 description 9
• 230000018109 developmental process Effects 0.000 description 9
• 238000010304 firing Methods 0.000 description 9
• 125000000623 heterocyclic group Chemical group 0.000 description 9
• 230000035800 maturation Effects 0.000 description 9
• 108040007629 peroxidase activity proteins Proteins 0.000 description 9
• 230000036278 prepulse Effects 0.000 description 9
• 230000009467 reduction Effects 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 239000003826 tablet Substances 0.000 description 9
• 239000003981 vehicle Substances 0.000 description 9
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
• 238000000540 analysis of variance Methods 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 125000003118 aryl group Chemical group 0.000 description 8
• 230000006736 behavioral deficit Effects 0.000 description 8
• 230000001419 dependent effect Effects 0.000 description 8
• 230000000763 evoking effect Effects 0.000 description 8
• 230000036749 excitatory postsynaptic potential Effects 0.000 description 8
• 230000000971 hippocampal effect Effects 0.000 description 8
• 230000002401 inhibitory effect Effects 0.000 description 8
• 230000003859 lipid peroxidation Effects 0.000 description 8
• 230000001537 neural effect Effects 0.000 description 8
• 102000004169 proteins and genes Human genes 0.000 description 8
• 125000001424 substituent group Chemical group 0.000 description 8
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
• 108010028326 Calbindin 2 Proteins 0.000 description 7
• 102100021849 Calretinin Human genes 0.000 description 7
• 241000699670 Mus sp. Species 0.000 description 7
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
• 150000002148 esters Chemical class 0.000 description 7
• 229940068196 placebo Drugs 0.000 description 7
• 239000000902 placebo Substances 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 235000018102 proteins Nutrition 0.000 description 7
• 238000010186 staining Methods 0.000 description 7
• 229930006000 Sucrose Natural products 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 125000000217 alkyl group Chemical group 0.000 description 6
• 102000014823 calbindin Human genes 0.000 description 6
• 108060001061 calbindin Proteins 0.000 description 6
• 235000001727 glucose Nutrition 0.000 description 6
• 210000004326 gyrus cinguli Anatomy 0.000 description 6
• 230000003834 intracellular effect Effects 0.000 description 6
• 238000001000 micrograph Methods 0.000 description 6
• 125000000896 monocarboxylic acid group Chemical group 0.000 description 6
• 230000006977 prepulse inhibition Effects 0.000 description 6
• 230000008569 process Effects 0.000 description 6
• 210000002763 pyramidal cell Anatomy 0.000 description 6
• 239000005720 sucrose Substances 0.000 description 6
• 230000009782 synaptic response Effects 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• 210000005111 ventral hippocampus Anatomy 0.000 description 6
• 241000282412 Homo Species 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 150000001298 alcohols Chemical class 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 230000001149 cognitive effect Effects 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 230000002939 deleterious effect Effects 0.000 description 5
• 239000003651 drinking water Substances 0.000 description 5
• 235000020188 drinking water Nutrition 0.000 description 5
• 235000019441 ethanol Nutrition 0.000 description 5
• 238000007912 intraperitoneal administration Methods 0.000 description 5
• 239000010410 layer Substances 0.000 description 5
• 239000003550 marker Substances 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 230000003647 oxidation Effects 0.000 description 5
• 238000007254 oxidation reaction Methods 0.000 description 5
• 230000002093 peripheral effect Effects 0.000 description 5
• CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 5
• 239000006187 pill Substances 0.000 description 5
• 238000012545 processing Methods 0.000 description 5
• FTSUPYGMFAPCFZ-ZWNOBZJWSA-N quinpirole Chemical compound C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 FTSUPYGMFAPCFZ-ZWNOBZJWSA-N 0.000 description 5
• 229950001037 quinpirole Drugs 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 238000001356 surgical procedure Methods 0.000 description 5
• 239000000375 suspending agent Substances 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
• 208000020925 Bipolar disease Diseases 0.000 description 4
• 229920002261 Corn starch Polymers 0.000 description 4
• 108020004414 DNA Proteins 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 235000010443 alginic acid Nutrition 0.000 description 4
• 229920000615 alginic acid Polymers 0.000 description 4
• 230000003542 behavioural effect Effects 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• 125000004432 carbon atom Chemical group C* 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 230000001771 impaired effect Effects 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 150000002535 isoprostanes Chemical class 0.000 description 4
• 239000002207 metabolite Substances 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 230000002360 prefrontal effect Effects 0.000 description 4
• 230000000069 prophylactic effect Effects 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 238000005070 sampling Methods 0.000 description 4
• 239000000377 silicon dioxide Substances 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 239000012453 solvate Substances 0.000 description 4
• 238000012421 spiking Methods 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 108060008226 thioredoxin Proteins 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 238000005550 wet granulation Methods 0.000 description 4
• UWYKXZBFDOWDHO-GRIHUTHFSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(2-aminoethyl)pentanamide;hydrochloride Chemical compound Cl.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCN)SC[C@@H]21 UWYKXZBFDOWDHO-GRIHUTHFSA-N 0.000 description 3
• 206010002091 Anaesthesia Diseases 0.000 description 3
• 108091006146 Channels Proteins 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
• 229920000881 Modified starch Polymers 0.000 description 3
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
• 102000004316 Oxidoreductases Human genes 0.000 description 3
• 108090000854 Oxidoreductases Proteins 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 3
• 102100036407 Thioredoxin Human genes 0.000 description 3
• 229920001615 Tragacanth Polymers 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 125000003545 alkoxy group Chemical group 0.000 description 3
• 230000037005 anaesthesia Effects 0.000 description 3
• 239000000305 astragalus gummifer gum Substances 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• 230000027455 binding Effects 0.000 description 3
• 230000036983 biotransformation Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 230000006727 cell loss Effects 0.000 description 3
• 210000003710 cerebral cortex Anatomy 0.000 description 3
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 239000008120 corn starch Substances 0.000 description 3
• 229940099112 cornstarch Drugs 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 230000004064 dysfunction Effects 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 125000005843 halogen group Chemical group 0.000 description 3
• 230000004694 hippocampus damage Effects 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
• 229960004903 invert sugar Drugs 0.000 description 3
• 239000011777 magnesium Substances 0.000 description 3
• 230000010534 mechanism of action Effects 0.000 description 3
• 239000008108 microcrystalline cellulose Substances 0.000 description 3
• 229940016286 microcrystalline cellulose Drugs 0.000 description 3
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
• 230000001123 neurodevelopmental effect Effects 0.000 description 3
• 231100000189 neurotoxic Toxicity 0.000 description 3
• 230000002887 neurotoxic effect Effects 0.000 description 3
• 231100000706 no observed effect level Toxicity 0.000 description 3
• 230000007310 pathophysiology Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 230000036470 plasma concentration Effects 0.000 description 3
• 238000011552 rat model Methods 0.000 description 3
• 238000011808 rodent model Methods 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 238000004611 spectroscopical analysis Methods 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 230000035882 stress Effects 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• TZGPACAKMCUCKX-UHFFFAOYSA-N 2-hydroxyacetamide Chemical class NC(=O)CO TZGPACAKMCUCKX-UHFFFAOYSA-N 0.000 description 2
• WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
• RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
• JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 2
• JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 2
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 240000008886 Ceratonia siliqua Species 0.000 description 2
• 235000013912 Ceratonia siliqua Nutrition 0.000 description 2
• 244000303965 Cyamopsis psoralioides Species 0.000 description 2
• 206010011903 Deafness traumatic Diseases 0.000 description 2
• 206010013142 Disinhibition Diseases 0.000 description 2
• 206010052804 Drug tolerance Diseases 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
• 108010044467 Isoenzymes Proteins 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 241000282567 Macaca fascicularis Species 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
• 108020005196 Mitochondrial DNA Proteins 0.000 description 2
• 102000004722 NADPH Oxidases Human genes 0.000 description 2
• 108010002998 NADPH Oxidases Proteins 0.000 description 2
• 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 229930040373 Paraformaldehyde Natural products 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 240000001058 Sterculia urens Species 0.000 description 2
• 235000015125 Sterculia urens Nutrition 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 206010052428 Wound Diseases 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 240000008042 Zea mays Species 0.000 description 2
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 230000036982 action potential Effects 0.000 description 2
• 239000000853 adhesive Substances 0.000 description 2
• 230000001070 adhesive effect Effects 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 229940072056 alginate Drugs 0.000 description 2
• 125000005907 alkyl ester group Chemical group 0.000 description 2
• SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
• 229960004046 apomorphine Drugs 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
• 238000013528 artificial neural network Methods 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 235000012216 bentonite Nutrition 0.000 description 2
• 230000002146 bilateral effect Effects 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 239000005388 borosilicate glass Substances 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229960005069 calcium Drugs 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000001110 calcium chloride Substances 0.000 description 2
• 235000011148 calcium chloride Nutrition 0.000 description 2
• 229910001628 calcium chloride Inorganic materials 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 210000005056 cell body Anatomy 0.000 description 2
• 229920002301 cellulose acetate Polymers 0.000 description 2
• 238000004296 chiral HPLC Methods 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000013375 chromatographic separation Methods 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 230000007278 cognition impairment Effects 0.000 description 2
• 208000010877 cognitive disease Diseases 0.000 description 2
• 238000012790 confirmation Methods 0.000 description 2
• 229920001577 copolymer Polymers 0.000 description 2
• 235000005822 corn Nutrition 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000007123 defense Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 238000001784 detoxification Methods 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• 210000005110 dorsal hippocampus Anatomy 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 230000008482 dysregulation Effects 0.000 description 2
• 238000002001 electrophysiology Methods 0.000 description 2
• 230000007831 electrophysiology Effects 0.000 description 2
• 239000012055 enteric layer Substances 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 231100000318 excitotoxic Toxicity 0.000 description 2
• 230000003492 excitotoxic effect Effects 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 239000008394 flocculating agent Substances 0.000 description 2
• 238000001640 fractional crystallisation Methods 0.000 description 2
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 229940050410 gluconate Drugs 0.000 description 2
• 229960001031 glucose Drugs 0.000 description 2
• 229940045883 glutathione disulfide Drugs 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 230000026781 habituation Effects 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 210000001320 hippocampus Anatomy 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
• 230000002102 hyperpolarization Effects 0.000 description 2
• 230000005934 immune activation Effects 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000010365 information processing Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 229960000367 inositol Drugs 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 238000002483 medication Methods 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 244000309715 mini pig Species 0.000 description 2
• 210000003470 mitochondria Anatomy 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 230000000324 neuroprotective effect Effects 0.000 description 2
• 238000006396 nitration reaction Methods 0.000 description 2
• 230000008599 nitrosative stress Effects 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 238000001543 one-way ANOVA Methods 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 230000003534 oscillatory effect Effects 0.000 description 2
• 239000007800 oxidant agent Substances 0.000 description 2
• 230000004792 oxidative damage Effects 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229920002866 paraformaldehyde Polymers 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 229920001277 pectin Polymers 0.000 description 2
• 235000010987 pectin Nutrition 0.000 description 2
• 239000001814 pectin Substances 0.000 description 2
• 239000008177 pharmaceutical agent Substances 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000004237 preparative chromatography Methods 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 208000020016 psychiatric disease Diseases 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 239000007845 reactive nitrogen species Substances 0.000 description 2
• 238000004064 recycling Methods 0.000 description 2
• 230000010282 redox signaling Effects 0.000 description 2
• 230000008929 regeneration Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 230000036390 resting membrane potential Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 230000000698 schizophrenic effect Effects 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 230000003595 spectral effect Effects 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 238000012453 sprague-dawley rat model Methods 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 229940032147 starch Drugs 0.000 description 2
• 230000000707 stereoselective effect Effects 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 230000000946 synaptic effect Effects 0.000 description 2
• 230000005062 synaptic transmission Effects 0.000 description 2
• 229920001059 synthetic polymer Polymers 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 230000000007 visual effect Effects 0.000 description 2
• 238000011179 visual inspection Methods 0.000 description 2
• 239000001993 wax Substances 0.000 description 2
• HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
• IRJCBFDCFXCWGO-SCSAIBSYSA-N (2r)-2-azaniumyl-2-(3-oxo-1,2-oxazol-5-yl)acetate Chemical compound [O-]C(=O)[C@H]([NH3+])C1=CC(=O)NO1 IRJCBFDCFXCWGO-SCSAIBSYSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
• OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
• KWTUCBZCJBVRTM-UHFFFAOYSA-N 2-$l^{1}-selanyl-n-phenylbenzamide Chemical compound [Se]C1=CC=CC=C1C(=O)NC1=CC=CC=C1 KWTUCBZCJBVRTM-UHFFFAOYSA-N 0.000 description 1
• KUXGUCNZFCVULO-UHFFFAOYSA-N 2-(4-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=C(OCCO)C=C1 KUXGUCNZFCVULO-UHFFFAOYSA-N 0.000 description 1
• IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
• MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
• SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• 239000012103 Alexa Fluor 488 Substances 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 101100337673 Caenorhabditis elegans gpx-1 gene Proteins 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 102000003952 Caspase 3 Human genes 0.000 description 1
• 108090000397 Caspase 3 Proteins 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 102000016938 Catalase Human genes 0.000 description 1
• 108010053835 Catalase Proteins 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 229920013683 Celanese Polymers 0.000 description 1
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 241000700112 Chinchilla Species 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 229920001287 Chondroitin sulfate Polymers 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 206010010144 Completed suicide Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 102000018832 Cytochromes Human genes 0.000 description 1
• 108010052832 Cytochromes Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 108020005124 DNA Adducts Proteins 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 101150049660 DRD2 gene Proteins 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 108050004812 Dopamine receptor Proteins 0.000 description 1
• 102000015554 Dopamine receptor Human genes 0.000 description 1
• 238000001061 Dunnett's test Methods 0.000 description 1
• 241001125671 Eretmochelys imbricata Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 102000004300 GABA-A Receptors Human genes 0.000 description 1
• 108090000839 GABA-A Receptors Proteins 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• 102000004263 Glutamate-Cysteine Ligase Human genes 0.000 description 1
• 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 1
• 108010063907 Glutathione Reductase Proteins 0.000 description 1
• 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 101000581533 Homo sapiens Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial Proteins 0.000 description 1
• 101000852559 Homo sapiens Thioredoxin Proteins 0.000 description 1
• 101710192641 Hydroperoxide reductase Proteins 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Natural products OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 1
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 208000034800 Leukoencephalopathies Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• 102100027320 Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial Human genes 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 125000003047 N-acetyl group Chemical group 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 229940123857 NADPH oxidase inhibitor Drugs 0.000 description 1
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
• 231100000229 OECD 452 Chronic Toxicity Study Toxicity 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 229920005372 Plexiglas® Polymers 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 229920001219 Polysorbate 40 Polymers 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• 240000009305 Pometia pinnata Species 0.000 description 1
• 235000017284 Pometia pinnata Nutrition 0.000 description 1
• 208000037048 Prodromal Symptoms Diseases 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 241000220010 Rhode Species 0.000 description 1
• 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
• 108091006629 SLC13A2 Proteins 0.000 description 1
• 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
• 108010074686 Selenoproteins Proteins 0.000 description 1
• 102000008114 Selenoproteins Human genes 0.000 description 1
• 239000004113 Sepiolite Substances 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 229910021607 Silver chloride Inorganic materials 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 229920006328 Styrofoam Polymers 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
• 102000019197 Superoxide Dismutase Human genes 0.000 description 1
• 108010012715 Superoxide dismutase Proteins 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 239000004809 Teflon Substances 0.000 description 1
• 229920006362 Teflon® Polymers 0.000 description 1
• 102000002933 Thioredoxin Human genes 0.000 description 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 244000098338 Triticum aestivum Species 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 150000001335 aliphatic alkanes Chemical class 0.000 description 1
• 150000001336 alkenes Chemical class 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 230000000181 anti-adherent effect Effects 0.000 description 1
• 239000003911 antiadherent Substances 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 229940114079 arachidonic acid Drugs 0.000 description 1
• 235000021342 arachidonic acid Nutrition 0.000 description 1
• 230000001174 ascending effect Effects 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 229960000892 attapulgite Drugs 0.000 description 1
• 229940090047 auto-injector Drugs 0.000 description 1
• JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
• 239000004327 boric acid Substances 0.000 description 1
• 230000004641 brain development Effects 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229910052793 cadmium Inorganic materials 0.000 description 1
• BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
• UBWYRXFZPXBISJ-UHFFFAOYSA-L calcium;2-hydroxypropanoate;trihydrate Chemical compound O.O.O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O UBWYRXFZPXBISJ-UHFFFAOYSA-L 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 229960001631 carbomer Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 229940096529 carboxypolymethylene Drugs 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000004203 carnauba wax Substances 0.000 description 1
• 235000013869 carnauba wax Nutrition 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000008809 cell oxidative stress Effects 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 230000004637 cellular stress Effects 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
• 229960002327 chloral hydrate Drugs 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 229940059329 chondroitin sulfate Drugs 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 229960004170 clozapine Drugs 0.000 description 1
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
• 229960003920 cocaine Drugs 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 238000004624 confocal microscopy Methods 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 229960003624 creatine Drugs 0.000 description 1
• 239000006046 creatine Substances 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 150000001924 cycloalkanes Chemical class 0.000 description 1
• HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000001120 cytoprotective effect Effects 0.000 description 1
• GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 210000001787 dendrite Anatomy 0.000 description 1
• 230000002999 depolarising effect Effects 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 239000010432 diamond Substances 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 230000003291 dopaminomimetic effect Effects 0.000 description 1
• 238000007908 dry granulation Methods 0.000 description 1
• 229940112141 dry powder inhaler Drugs 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 230000027721 electron transport chain Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 230000037149 energy metabolism Effects 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 230000002964 excitative effect Effects 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 150000002194 fatty esters Chemical class 0.000 description 1
• 239000007888 film coating Substances 0.000 description 1
• 238000009501 film coating Methods 0.000 description 1
• 239000012054 flavored emulsion Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 235000020375 flavoured syrup Nutrition 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 210000005153 frontal cortex Anatomy 0.000 description 1
• 210000001222 gaba-ergic neuron Anatomy 0.000 description 1
• 230000003371 gabaergic effect Effects 0.000 description 1
• 230000030279 gene silencing Effects 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 230000007387 gliosis Effects 0.000 description 1
• 229940049906 glutamate Drugs 0.000 description 1
• 229960002743 glutamine Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 210000004884 grey matter Anatomy 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• 230000010370 hearing loss Effects 0.000 description 1
• 231100000888 hearing loss Toxicity 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
• 229910000271 hectorite Inorganic materials 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 230000001744 histochemical effect Effects 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• 102000056461 human TXN Human genes 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
• 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
• 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
• 230000002631 hypothermal effect Effects 0.000 description 1
• 238000010191 image analysis Methods 0.000 description 1
• TWWVIHLFNDYKFN-UHFFFAOYSA-N imidazolidine;morpholine Chemical compound C1CNCN1.C1COCCN1 TWWVIHLFNDYKFN-UHFFFAOYSA-N 0.000 description 1
• MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical group C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 238000003365 immunocytochemistry Methods 0.000 description 1
• 238000003125 immunofluorescent labeling Methods 0.000 description 1
• 229940027941 immunoglobulin g Drugs 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 229940088592 immunologic factor Drugs 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
• 210000001926 inhibitory interneuron Anatomy 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 238000012562 intraclass correlation Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229960001855 mannitol Drugs 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000004065 mitochondrial dysfunction Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 235000019799 monosodium phosphate Nutrition 0.000 description 1
• 210000000337 motor cortex Anatomy 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 210000005012 myelin Anatomy 0.000 description 1
• 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229920001206 natural gum Polymers 0.000 description 1
• 229920005615 natural polymer Polymers 0.000 description 1
• 230000001722 neurochemical effect Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000007472 neurodevelopment Effects 0.000 description 1
• 230000009223 neuronal apoptosis Effects 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 230000007171 neuropathology Effects 0.000 description 1
• 239000004090 neuroprotective agent Substances 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 231100001079 no serious adverse effect Toxicity 0.000 description 1
• 229940073555 nonoxynol-10 Drugs 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 150000007523 nucleic acids Chemical group 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000012053 oil suspension Substances 0.000 description 1
• 229960005017 olanzapine Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 229940054010 other antipsychotics in atc Drugs 0.000 description 1
• 230000008789 oxidative DNA damage Effects 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 230000010421 oxidative-nitrosative stress Effects 0.000 description 1
• 239000006174 pH buffer Substances 0.000 description 1
• 235000019629 palatability Nutrition 0.000 description 1
• 229960001057 paliperidone Drugs 0.000 description 1
• 229910052625 palygorskite Inorganic materials 0.000 description 1
• 239000003182 parenteral nutrition solution Substances 0.000 description 1
• 230000004796 pathophysiological change Effects 0.000 description 1
• 230000004963 pathophysiological condition Effects 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229960000292 pectin Drugs 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
• 230000008447 perception Effects 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 238000005502 peroxidation Methods 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000008105 phosphatidylcholines Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 229920000867 polyelectrolyte Polymers 0.000 description 1
• 229920000193 polymethacrylate Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
• 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
• 229920001184 polypeptide Chemical group 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 229940068977 polysorbate 20 Drugs 0.000 description 1
• 229940101027 polysorbate 40 Drugs 0.000 description 1
• 229940113124 polysorbate 60 Drugs 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
• 238000010149 post-hoc-test Methods 0.000 description 1
• 230000007542 postnatal development Effects 0.000 description 1
• 235000011056 potassium acetate Nutrition 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003334 potential effect Effects 0.000 description 1
• 210000005032 pre-frontal cortical neuron Anatomy 0.000 description 1
• 230000003244 pro-oxidative effect Effects 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 108090000765 processed proteins & peptides Chemical group 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 238000013102 re-test Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 229910052624 sepiolite Inorganic materials 0.000 description 1
• 235000019355 sepiolite Nutrition 0.000 description 1
• 230000009919 sequestration Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• 239000000344 soap Substances 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
• APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 229960002920 sorbitol Drugs 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 230000024188 startle response Effects 0.000 description 1
• 229940102548 stearalkonium hectorite Drugs 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 238000004326 stimulated echo acquisition mode for imaging Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 239000008261 styrofoam Substances 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 239000001384 succinic acid Substances 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000007939 sustained release tablet Substances 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 230000003956 synaptic plasticity Effects 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229940094937 thioredoxin Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 231100000041 toxicology testing Toxicity 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000012549 training Methods 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 239000010937 tungsten Substances 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 239000002691 unilamellar liposome Substances 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 238000012795 verification Methods 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 238000010865 video microscopy Methods 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• 210000004885 white matter Anatomy 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1